Using Ciprofol for Sedation During Liver Cancer Treatment
Efficacy and Safety of Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation: A Double-Blind, Randomized, Noninferiority Trial
NA · Zhejiang Cancer Hospital · NCT06178926
This study is testing if Ciprofol can provide better sedation for people aged 18-75 during liver cancer treatment compared to the usual sedation methods.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Zhejiang Cancer Hospital (other) |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06178926 on ClinicalTrials.gov |
What this trial studies
This study evaluates the efficacy and safety of Ciprofol sedation in patients undergoing ultrasound-guided percutaneous radiofrequency ablation for liver tumors. Patients aged 18-75 with specific health criteria will receive Ciprofol injections prior to the procedure, and sedation levels will be monitored to ensure adequate sedation. The goal is to determine how well Ciprofol works compared to traditional sedation methods like Propofol in this context.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 who are scheduled for liver tumor ablation and meet specific health criteria.
Not a fit: Patients with known allergies to propofol or Ciprofol, serious organ dysfunction, or recent significant cardiac events may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a safer and more effective sedation option for patients undergoing liver cancer treatment.
How similar studies have performed: While the use of Ciprofol is relatively novel in this specific context, similar sedation approaches have shown promise in other medical procedures.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who intend to undergoing ultrasound-guided percutaneous radiofrequency ablation of liver tumors; * Age: 18-75 years old; * ASA grade I-III; * Laboratory examination meets the following conditions: neutrophils \>1.5×109/L, platelet \>80×109/L, hemoglobin \>90g/L, aspartate transferase \<1.5×ULN, total bilirubin \<1.5×ULN, serum creatinine \<1.2 x ULN; * Chemotherapy \< 4 times. Exclusion Criteria: * Patients who are known to be allergic to propofol, opioids, eggs, soy products, or patients who are contraindicated with these drugs or foods due to illness; * serious organ dysfunction and other systemic diseases, such as liver dysfunction, renal dysfunction; Worsening congestive heart failure within the last 6 months resulting in hospitalization or adjustment of medication; Severe aortic or mitral stenosis; Heart surgery (heart valve replacement) within the last 6 months; Acute myocardial infarction in the last 6 months; Hemodynamic disturbance due to arrhythmia; Respiratory diseases; Cerebrovascular diseases; . Taking propofol, opioids or other analgesic and sedative drugs 72 hours before . Emergency surgery; * Those who are unable to communicate with the researcher normally or who are deemed unsuitable by the researcher and refuse to participate in the study.
Where this trial is running
Hangzhou, Zhejiang
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (RECRUITING)
Study contacts
- Principal investigator: Jiangling Wang, Dr. — Zhejiang Cancer Hospital
- Study coordinator: Xiaochun Jin, MD.
- Email: ec@zjcc.org.cn
- Phone: +86 571-88122564
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Liver Cancer, Ciprofol, Radiofreqency ablation